CN1310673C - 含多肽的多分散混合物的组合物及其药物组合物 - Google Patents
含多肽的多分散混合物的组合物及其药物组合物 Download PDFInfo
- Publication number
- CN1310673C CN1310673C CNB200410064296XA CN200410064296A CN1310673C CN 1310673 C CN1310673 C CN 1310673C CN B200410064296X A CNB200410064296X A CN B200410064296XA CN 200410064296 A CN200410064296 A CN 200410064296A CN 1310673 C CN1310673 C CN 1310673C
- Authority
- CN
- China
- Prior art keywords
- mixture
- kilodalton
- polypeptide
- compositions
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rehabilitation Therapy (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyamides (AREA)
Abstract
本发明提供了一种组合物,该组合物包含多肽的一种多分散混合物,所述多肽由谷氨酸、赖氨酸、丙胺酸和酪氨酸组成,其中所述混合物具有的平均分子量为约4-9千道尔顿。本发明还提供了一种用于治疗多发性硬化症的药物组合物,其包含治疗有效剂量的上述组合物。
Description
本申请是申请日为1995年5月23日、发明创造名称为“共聚物组成改进的共聚物-1”的中国专利申请(国家申请号为95194101.1,国际申请号为PCT/US95/06551)的分案申请。
本申请是1994年11月23日递交的U.S.S.N.08/344248的部分后续申请,该申请是1994年5月24日递交的U.S.S.N.08/248037的后续。
发明背景
共聚物-1是髓鞘碱性蛋白(MBP)的合成多肽类似物,髓鞘碱性蛋白是髓鞘的天然成分。已表明其是多发性硬化症的有效的治疗剂(欧洲免疫学杂志[1971]1:242;神经科学杂志[1977]31:433)。本文所引用的所有参考文献都引入本文以供参考。早在50年代,在多发性硬化症的免疫疗法中对共聚物-1的观察表明髓鞘碱性蛋白成分,如MBP可阻止或控制实验性自身免疫脑脊髓炎(EAE)。EAE是一种诱发于敏感动物的类似于多发性硬化症的疾病。
共聚物-1是由Drs.Sela、Arnon及其合作者在Weizmann研究所(Rehovot,以色列)研究的。据示它可抑制EAE(欧洲免疫学杂志[1971]1:242;美国专利3,849,550)。最近表明共聚物-1有利于缓解多发性硬化症的恶化(新英格兰医学杂志[1987]317:406)。采用每日注射共聚物-1治疗的患者与对照组患者相比几乎没有恶化并且他们的残疾加剧较轻微。
共聚物-1是多肽的混合物,由丙氨酸、谷氨酸、赖氨酸和酪氨酸组成,摩尔比约为6∶2∶5∶1。它是通过化学聚合四种氨基酸形成的产物(平均分子量为23000道尔顿)而合成的(美国专利3849550)。
本发明的目的是提供一种改进组成的共聚物-1。
发明概述
本发明涉及一种共聚物-1组合物,该组合物基本上不含分子量大于40千道尔顿(KDa)的共聚物-1种类。
本发明另外涉及一种在分子量约为2KDa至20KDa范围内摩尔分级超过75%的共聚物-1。
另外,本发明涉及一种平均分子量约为4至8.6KDa的共聚物-1。
此外,本发明涉及一种药物组合物的以及用上述共聚物-1治疗多发性硬化症的方法。
附图简述
图1表示三批共聚物-1的分子量分布,显示出分子量大于40KDa种类的比例。图2表示与摩尔分级有关的相似数据。
发明详述
本发明涉及一种共聚物-1组合物,该组合物基本上不含分子量大于40千道尔顿(KDa)的共聚物-1种类。优选地,该组合物含有少于5%的分子量为40KDa或更高的共聚物-1种类。更优选该组合物含有少于2.5%的分子量为40KDa或更高的共聚物-1种类。
本发明另外涉及一种在分子量约为2KDa至20KDa范围内摩尔分级超过75%的共聚物-1。
此外,本发明涉及一种平均分子量约为4至8.6KDa的共聚物-1。更具体地说,本发明涉及一种平均分子量约为4至8KDa的共聚物-1以及平均分子量约为6.25至8.4KDa的共聚物-1。
本发明的共聚物-1可以通过本领域已知的方法制备,例如美国专利3849550中公开的方法,其中于环境温度将酪氨酸、丙氨酸、γ-谷氨酸苄酯以及E-N-三氟乙酰赖氨酸的N-羧酸酐在无水二烷中聚合,二乙胺作为引发剂。用溴化氢的冰醋酸溶液脱去谷氨酸的γ-羧基,然后用1M哌啶从赖氨酸残基上除去三氟乙酰基。对于本发明的目的而言,术语“环境温度”和“室温”应理解成从约20至约26℃的温度。
具有所需范围分子量的共聚物-1可以通过已知方法获得。该类方法包括将含有高分子量种类的共聚物-1进行色谱并收集不含非所需种类的部分,或者通过部分酸或酶水解除去高分子量的种类,其后通过透析或超滤进行纯化。另外获得所需分子量范围的共聚物-1的方法是通过制备氨基酸是被保护的所需种类,然后直接除去保护即得所需种类。本发明的组合物可以通过本领域常规的已知方法配制。优选地,将组合物冻干并制成适于皮下注射用的水溶液。可任选地,也可将共聚物-1配制成本领域已知的用于制备肽类药物的口服、鼻用、口腔用或直肠用制剂的各种形式。
典型地,每日以20mg的剂量将共聚物-1给予多发性硬化症患者。
本发明通过下述实施例说明,但并非限定本发明。
实施例1
制备低毒性共聚物-1的色谱法
按照本领域已知的方法如美国专利3849550的方法制备两组共聚物-1。
如下文所述将一组用色谱分离。
在Superformance 26Merck药筒中按照生产商的说明制备凝胶过滤用柱-FRACTOGEL TSK HW55(600×26mm)。将此柱用水平衡,注射丙酮溶液用于总体积测定。用0.2M的乙酸铵缓冲液(pH5.0)平衡该柱。将30ml共聚物-1样品(20mg/ml,在0.2M pH值为5.0的乙酸铵中)装上柱,每10分钟收集一次级分。在120-130分钟之间分离含有平均分子量为7-8KDa的级分(A批)。
分子量分析
在UVIKON 810分光光度计上测定275nm的紫外吸收。将样品稀释以获得低于1个吸收单位的紫外吸收。在校准后的凝胶过滤柱(Superose 12)上测定两批产品的分子分布。
发明共聚物-1的A批平均分子量为7-8KDa。该批产品的2.5%具有高于32KDa的分子量,但是在该批产品中不存在分子量高于40KDa的共聚物-1种类。
共聚物-1的另一批(不进行色谱法)平均分子量为12KDa。该批产品的2.5%具有高于42KDa的分子量,该批产品中总共聚物-1种类的5%具有高于40KDa的分子量。
实施例2
毒性分析
A:体内
将平均分子量为7.3和8.4KDa(低于2.5%的共聚物-1种类超过40KDa)和22KDa(多于5%的共聚物-1种类超过40KDa)的三批共聚物-1进行如下毒性试验。在每种情况下每个实验组使用5只小鼠。
方法
将共聚物-1溶于蒸馏水中得到含2mg/ml的活性成分的溶液。将0.5ml测试溶液注射到每只小鼠的外侧尾静脉。观察48小时期间中小鼠的死亡率和相关临床症状。注射后10分钟、24小时和48小时记录观察结果。如果在48小时后,全部动物仍存活并且没有观察到不良症状,则指明该组为“无毒”。但是,如果有一只或多只的小鼠死亡或者表现出不痕症状,则指明该组为“毒性”。
平均分子量为7.3和8.4KDa批的产品都被指明是“无毒”,而平均分子量为22KDa的组在48小时后,5只小鼠中有3只死亡,因此指明其为“毒性”。
B:体外
RBL-脱颗粒试验
I.引言
噬碱细胞释放的组胺(或者5-羟色胺)是一种直接过敏性的体外模型。将大鼠噬碱白细胞系(RBL-2H3)培养成特征为高敏、均一、易于在培养物及再生体系中维持的细胞系(E.L.Basumian,C.Isersky,M.G.petrino和R.P.Siraganian.欧洲免疫学杂志11,317(1981))。组胺释放的生理剌激包括抗原结合到膜结合IgE分子上,导致后者交联,然后引发复杂的生化级联。除了这些生理性免疫球蛋白介导的引发剂以外,也可通过不同的非IgE介导刺激诱导脱粒。其中有各种肽类和合成聚合物,例如聚赖氨酸(R.P.Siraganan.药理学动向,10月,432(1983))。因此,用RBL脱粒试验筛选出可引起脱粒从而导致有害的局部和/或全身副作用的共聚物-1。
II.试验方法原理
将大鼠噬碱白细胞(RBL-2H3)用[3H]-5-羟色胺加载,然后与100μg待测共聚物-1一起培养。可诱导非特异性脱粒的共聚物-1组可将[3H]-5-羟色胺释放到培养基中。通过液闪计数仪计数培养基中的放射性,在沉淀细胞中测定结合到细胞中的总放射标记的5-羟色胺。脱粒百分数是以从总结合中的释放出的5-羟色胺百分比计算的。
III.结果
分析平均分子量在6,250-14,500之间的四批共聚物-1的分子量大于40KDa种类的和RBL脱粒的百分数%。结果汇总于下表。
平均分子量(道尔顿) | 分子量大于40KDa种类的百分数(%) | 5-羟色胺释放百分数(%) |
6,250 | <2.5 | 12.4 |
7,300 | <2.5 | 21.0 |
13,000 | >5 | 66.9 |
14,500 | >5 | 67.8 |
从中可看出,当高分子量种类的百分数低时(<2.5),5-羟色胺的释放百分数(表示毒性)则低,反之亦然。
实施例3
三氟乙酰基-共聚物-1的制备
按照Teitelbaum等在《欧洲免疫学杂志》第1卷第242页(1971)中描述的方法由溶于3.5升二烷中的酪氨酸的N-羧酸酐(18g)、丙氨酸(50g)、γ-谷氨酸苄酯(35g)的N-羧酸酐和三氟乙酰赖氨酸制备保护起来的共聚物-1。
通过加入0.01-0.02%二乙胺引发聚合过程。将反应混合物于室温搅拌24小时,然后倒入10升水中。过滤产物(被保护的共聚物-1),用水洗涤并干燥。室温下用33%氢溴酸的冰醋酸溶液搅拌处理被保护的共聚物-1 6至12小时以除去谷氨酸盐中γ苄基保护基。将产物倒入过量水中,过滤,洗涤并干燥,得到三氟乙酰基-共聚物-1。
实施例4
三氟乙酰基-共聚物-1的制备
按照Teitelbaum等在《欧洲免疫学杂志》第1卷第242页(1971)中描述的方法由溶于3.5升二烷中的酪氨酸的N-羧酸酐(18g)、丙氨酸(50g)、γ-谷氨酸苄酯(35g)和三氟乙酰赖氨酸制备保护起来的共聚物-1。
通过进入0.01-0.02%二乙胺引发聚合过程。将反应混合物于室温搅拌24小时。然后倒入10升水中。过滤产物(被保护的共聚物-1),用水洗涤并干燥。
用33%HBr的冰醋酸溶液处理被保护的共聚物-1以从谷氨酸残基的5-甲酸酯中除去Ω苄基保护基并且将聚合物分裂成较小的多肽。获得分子量为7,000±2,000道尔顿的共聚物-1所需时间取决于反应温度和被保护的共聚物-1的大小。在20-28℃之间的温度于不同时间段如10-50小时对每批产品进行测试反应。计算有关这些小规模反应的分子量结果,描绘分子量对时间的曲线。由该曲线计算获得平均分子量为7000±2,000道尔顿的共聚物-1所需时间并将其应用于较大规模的反应中。平均而言,在26℃操作的时间为17小时。将产物倒入过量水中,过滤,洗涤并干燥,得到三氟乙酰基-共聚物-1。
低毒性共聚物-1的制备
将20g三氟乙酰基-共聚物-1分散在1升水中,加入100g哌啶。室温搅拌混合物24小时,过滤。将粗共聚物-1溶液分配到透析袋中,于10-20℃水中透析,直至达到pH=8。然后将其在约0.3%乙酸中透析,再用水透析直至达到pH=5.5-6.0。然后将溶液浓缩并冻干。
Claims (29)
1.一种共聚物-1组合物,包含多肽的混合物,由谷氨酸、赖氨酸、丙氨酸和酪氨酸组成,其中所述混合物具有的平均分子量为约4-9千道尔顿,其中所述多肽的混合物在分子量和序列上是非均一的,且其中,该组合物适用于治疗多发性硬化症。
2.权利要求1的组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
3.权利要求1的组合物,其中以摩尔分级为基的所述混合物中少于5%的多肽具有的分子量超过40千道尔顿。
4.权利要求3的组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
5.权利要求4的组合物,其中所述混合物具有的平均分子量为6.25-8.4千道尔顿。
6.权利要求1的组合物,其中所述混合物具有的平均分子量为约4-8.6千道尔顿。
7.权利要求1的组合物,其中所述混合物具有的平均分子量为约5-9千道尔顿。
8.权利要求1的组合物,其中以摩尔分级为基的所述混合物中少于2.5%的多肽具有的分子量超过40千道尔顿。
9.权利要求8的组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
10.权利要求9的组合物,其中所述混合物具有的平均分子量为6.25-8.4千道尔顿。
11.权利要求1的组合物,其中所述混合物具有基本上如附图1或附图2的曲线所示的分子量分布,其中平均分子量为约7.7千道尔顿。
12.一种药物组合物,其包含:
用于治疗多发性硬化症的治疗有效剂量的共聚物-1组合物,其中该共聚物-1组合物包含多肽的混合物,由谷氨酸、赖氨酸、丙氨酸和酪氨酸组成,其中所述混合物具有的平均分子量为约4-9千道尔顿,其中所述多肽的混合物在分子量和序列上是非均一的;和
药学上可接受的赋形剂。
13.权利要求12的药物组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
14.权利要求12的药物组合物,其中以摩尔分级为基的所述混合物中少于5%的多肽具有的分子量超过40千道尔顿。
15.权利要求14的药物组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
16.权利要求15的药物组合物,其中所述混合物具有的平均分子量为6.25-8.4千道尔顿。
17.权利要求12的药物组合物,其中所述混合物具有的平均分子量为约4-8.6千道尔顿。
18.权利要求12的药物组合物,其中所述混合物具有的平均分子量为约5-9千道尔顿。
19.权利要求12的药物组合物,其中以摩尔分级为基的所述混合物中少于2.5%的多肽具有的分子量超过40千道尔顿。
20.权利要求19的药物组合物,其中以摩尔分级为基的所述混合物中超过75%的多肽具有的分子量在约为2-20千道尔顿范围内。
21.权利要求20的药物组合物,其中所述混合物具有的平均分子量为6.25-8.4千道尔顿。
22.权利要求12的药物组合物,其中所述混合物具有基本上如附图1或附图2的曲线所示的分子量分布,其中平均分子量为约7.7千道尔顿。
23.权利要求12-22中任一项的药物组合物在制备治疗患有多发性硬化症患者的药物中的用途。
24.一种制备分子量为4-9千道尔顿的共聚物-1组合物的方法,该方法包括:
将摩尔比为1∶5∶2∶4的酪氨酸的N-羧酸酐、丙氨酸的N-羧酸酐、γ-谷氨酸苄酯和三氟乙酰赖氨酸的混合物进行聚合,形成被保护的多肽的混合物;
将该被保护的多肽脱保护,形成未保护的多肽混合物;和
将由谷氨酸、赖氨酸、丙氨酸和酪氨酸构成的未保护的多肽的共聚物-1组合物分离,其中所述共聚物-1组合物具有的平均分子量为4-9千道尔顿。
25.权利要求24的方法,其中所述的共聚物-1组合物具有的平均分子量为6.25-8.4千道尔顿。
26.平均分子量为约4-9千道尔顿的共聚物-1组合物,该组合物可由包括下列步骤的方法制备:
将摩尔比为1∶5∶2∶4的酪氨酸的N-羧酸酐、丙氨酸的N-羧酸酐、γ-谷氨酸苄酯和三氟乙酰赖氨酸的混合物进行聚合,形成被保护的多肽的混合物;
将该被保护的多肽脱保护,形成未保护的多肽混合物;和
将由谷氨酸、赖氨酸、丙氨酸和酪氨酸构成的未保护的多肽的混合物分离,其中所述的混合物具有的平均分子量为4-9千道尔顿。
27.权利要求26的组合物,其中所述的混合物具有的平均分子量为6.25-8.4千道尔顿。
28.一种共聚物-1组合物,包含多肽的混合物,由谷氨酸、赖氨酸、丙氨酸和酪氨酸组成,其中所述混合物具有的平均分子量为约4-9千道尔顿,其中所述多肽的混合物在分子量和序列上是非均一的,且其中,根据RBL-脱颗粒试验,该组合物与分子量大于9千道尔顿的共聚物-1组合物相比,显示出较低的毒性。
29.权利要求28的组合物,其中所述的混合物具有的平均分子量为6.25-8.4千道尔顿。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24803794A | 1994-05-24 | 1994-05-24 | |
US248037 | 1994-05-24 | ||
US34424894A | 1994-11-23 | 1994-11-23 | |
US344248 | 1994-11-23 | ||
PCT/US1995/006551 WO1995031990A1 (en) | 1994-05-24 | 1995-05-23 | Copolymer-1 improvements in compositions of copolymers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB951941011A Division CN1174753C (zh) | 1994-05-24 | 1995-05-23 | 共聚物组成改进的共聚物-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1626238A CN1626238A (zh) | 2005-06-15 |
CN1310673C true CN1310673C (zh) | 2007-04-18 |
Family
ID=26939072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB951941011A Expired - Lifetime CN1174753C (zh) | 1994-05-24 | 1995-05-23 | 共聚物组成改进的共聚物-1 |
CNB200410064296XA Expired - Lifetime CN1310673C (zh) | 1994-05-24 | 1995-05-23 | 含多肽的多分散混合物的组合物及其药物组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB951941011A Expired - Lifetime CN1174753C (zh) | 1994-05-24 | 1995-05-23 | 共聚物组成改进的共聚物-1 |
Country Status (31)
Country | Link |
---|---|
US (11) | US5800808A (zh) |
EP (1) | EP0762888B1 (zh) |
JP (2) | JPH10500955A (zh) |
KR (1) | KR100403750B1 (zh) |
CN (2) | CN1174753C (zh) |
AT (1) | ATE212857T1 (zh) |
AU (1) | AU2602195A (zh) |
BR (2) | BRPI9507758B1 (zh) |
CA (1) | CA2191088C (zh) |
CZ (1) | CZ292247B6 (zh) |
DE (2) | DE69525340T2 (zh) |
DK (1) | DK0762888T3 (zh) |
EE (1) | EE03423B1 (zh) |
ES (1) | ES2172586T3 (zh) |
FI (1) | FI120236B (zh) |
GE (1) | GEP20002205B (zh) |
HK (1) | HK1008657A1 (zh) |
HU (1) | HU223473B1 (zh) |
IL (2) | IL113812A (zh) |
LU (1) | LU90987I2 (zh) |
MD (1) | MD1443G2 (zh) |
NL (1) | NL300096I2 (zh) |
NO (1) | NO324528B1 (zh) |
NZ (1) | NZ287335A (zh) |
PL (1) | PL181026B1 (zh) |
PT (1) | PT762888E (zh) |
SI (1) | SI0762888T1 (zh) |
SK (1) | SK283699B6 (zh) |
TJ (1) | TJ392B (zh) |
UA (1) | UA62908C2 (zh) |
WO (1) | WO1995031990A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104371012A (zh) * | 2013-08-12 | 2015-02-25 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
US10259909B2 (en) | 2014-09-26 | 2019-04-16 | Hybio Pharmaceutical Co., Ltd. | Method for preparing glatiramer acetate |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
US7090982B2 (en) | 1991-10-22 | 2006-08-15 | The Governors Of The University Of Alberta | Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
AU2868699A (en) * | 1998-02-13 | 1999-08-30 | Autoimmune, Inc. | Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
AU766498B2 (en) | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
HU229720B1 (en) | 1998-09-25 | 2014-05-28 | Yeda Res & Dev | Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000020010A1 (en) * | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
US7083777B1 (en) | 1999-04-02 | 2006-08-01 | The Brigham And Women's Hospital, Inc. | Immunomodulating polymers |
JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー1、関連ペプチド及びポリペプチドならびにそれらによって処理されたt細胞の使用 |
ATE329608T1 (de) * | 2000-02-18 | 2006-07-15 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
IL153236A0 (en) * | 2000-06-05 | 2003-07-06 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
CN100438906C (zh) * | 2000-06-07 | 2008-12-03 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途 |
AU6887101A (en) * | 2000-06-20 | 2002-01-02 | Caprion Pharmaceuticals, Inc. | Copolymers and methods of treating prion-related diseases |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
IL137460A0 (en) | 2000-07-24 | 2001-07-24 | Yeda Res & Dev | Identifying antigen clusters for monitoring a global state of an immune system |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
GB2369896A (en) | 2000-12-06 | 2002-06-12 | Marconi Comm Ltd | Tunable optical filter actuator |
KR100442122B1 (ko) * | 2001-07-31 | 2004-07-30 | 한국전기연구원 | 영구 자석을 이용한 브러시리스 발전기 |
DE60237170D1 (de) * | 2001-12-04 | 2010-09-09 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
CA2469092C (en) * | 2001-12-06 | 2013-02-19 | Yeda Research And Development Co. Ltd | Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als) |
US20060057107A1 (en) * | 2001-12-21 | 2006-03-16 | Shaked Ze Ev | Combination treatment for multiple sclerosis |
ES2386435T3 (es) | 2003-01-07 | 2012-08-21 | Yeda Research And Development Co., Ltd. | Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica |
SI1592384T1 (sl) * | 2003-01-21 | 2013-03-29 | Yeda Research And Development Co., Ltd. The Weizmann Institute Of Science | Kopolimer 1 za zdravljenje vnetnih ÄŤrevesnih bolezni |
WO2004091573A1 (en) * | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
EP1638581A2 (en) | 2003-03-31 | 2006-03-29 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
EP1680087A1 (en) * | 2003-10-31 | 2006-07-19 | Teva Pharmaceutical Industries Limited | Nanoparticles for drug delivery |
EP2301569B1 (en) | 2003-11-12 | 2018-05-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
AU2004297044B2 (en) | 2003-12-09 | 2010-12-09 | Yeda Research And Development Co. Ltd. | Method and vaccine comprising Copolymer 1 for treatment of psychiatric disorders |
AU2005211424A1 (en) * | 2004-02-02 | 2005-08-18 | Mixture Sciences, Inc. | Peptide mixtures with immunomodulatory activity |
KR20060125916A (ko) * | 2004-03-01 | 2006-12-06 | 펩팀문, 인코포레이티드 | 자가면역 질병을 치료하기 위한 방법 및 조성물 |
EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
US20050260770A1 (en) * | 2004-04-01 | 2005-11-24 | Cohen Irun R | Antigen array and diagnostic uses thereof |
JP2007536278A (ja) | 2004-05-07 | 2007-12-13 | ペプチミューン,インコーポレイテッド | ランダム共重合体を用いる疾患の治療方法 |
US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
ES2432369T3 (es) | 2004-06-25 | 2013-12-03 | Id Biomedical Corporation Of Quebec | Composiciones y métodos para tratar trastornos neurológicos |
EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
WO2006029393A2 (en) * | 2004-09-09 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
EP1807467B1 (en) * | 2004-10-29 | 2009-08-26 | Sandoz AG | Processes for preparing glatiramer |
US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
US20090191173A1 (en) * | 2004-11-29 | 2009-07-30 | Michal Eisenbach-Schwartz | Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 |
WO2006083608A1 (en) * | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
EP1891233A4 (en) * | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
JP5374363B2 (ja) * | 2006-04-28 | 2013-12-25 | モメンタ ファーマシューティカルズ インコーポレイテッド | ペプチド混合物を評価する方法 |
KR100831796B1 (ko) * | 2006-05-29 | 2008-05-28 | 엘지전자 주식회사 | 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법 |
ES2605154T3 (es) | 2006-06-28 | 2017-03-13 | Yeda Research And Development Company Limited | Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad |
ATE452140T1 (de) * | 2006-07-05 | 2010-01-15 | Momenta Pharmaceuticals Inc | Verbessertes verfahren zur herstellung von copolymer-1 |
EP2381254B2 (en) | 2007-06-21 | 2017-07-19 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
US20090029766A1 (en) * | 2007-07-26 | 2009-01-29 | Lutnick Howard W | Amusement gaming access and authorization point |
EP2173766A1 (en) * | 2007-07-31 | 2010-04-14 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
EP2586460A1 (en) | 2007-10-16 | 2013-05-01 | Peptimmune, Inc. | Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes |
WO2009062132A2 (en) | 2007-11-09 | 2009-05-14 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
CA2702437C (en) * | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
RU2010146489A (ru) | 2008-04-16 | 2012-05-27 | Момента Фармасьютикалз, Инк. (Us) | Анализ композиций сополимера аминокислот |
HUE025042T2 (en) * | 2008-08-07 | 2016-07-28 | Sigma Aldrich Co Llc | High-yield production of low molecular weight polylysine and poliornitine |
US8212002B2 (en) * | 2008-08-07 | 2012-07-03 | Scinopharm Taiwan Ltd | Synthesis of glatiramer acetate |
US9617313B2 (en) | 2008-12-24 | 2017-04-11 | Synthon Bv | Process for purifying a polymer mixture |
EP2414384B2 (en) | 2009-04-03 | 2023-05-03 | Momenta Pharmaceuticals, Inc. | Control of copolymer compositions |
WO2010140157A1 (en) * | 2009-06-04 | 2010-12-09 | Council Of Scientific & Industrial Research | Aprocess for the preparation of copolymer - 1 (cop-i), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine-drug for the treatment of multiple sclerosis |
PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
US8691790B2 (en) * | 2009-07-27 | 2014-04-08 | James Layne Boucher | Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy |
PT2405749E (pt) | 2009-08-20 | 2013-07-22 | Yeda Res & Dev | Terapia de acetato de glatirâmero de baixa frequência |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
PT3536333T (pt) | 2010-01-04 | 2022-11-11 | Mapi Pharma Ltd | Sistema de depósito compreendendo acetato de glatirâmero |
WO2011086470A1 (en) | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
ES2694100T3 (es) | 2010-04-07 | 2018-12-18 | California Institute Of Technology | Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados |
CA2797227A1 (en) * | 2010-04-27 | 2011-11-10 | Dr. Reddy's Laboratories Ltd. | Preparation of polypeptides and salts thereof |
WO2011146910A1 (en) | 2010-05-20 | 2011-11-24 | Round June L | Antigen specific tregs and related compositions, methods and systems |
WO2012016042A2 (en) * | 2010-07-29 | 2012-02-02 | Dr. Reddy's Laboratories Ltd. | Glatiramer acetate molecular weight markers |
PT2627669T (pt) | 2010-10-11 | 2016-11-24 | Teva Pharma | Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero |
EP2675824B1 (en) | 2011-02-14 | 2017-09-27 | USV Private Limited | Copolymer-1, process for preparation and analytical methods thereof |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
WO2012150495A1 (en) | 2011-05-05 | 2012-11-08 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
WO2013009864A1 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Structure assessment of heterogeneous polypeptide mixtures |
WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
EP2642290A1 (en) | 2012-03-19 | 2013-09-25 | Synthon BV | Glatiramer acetate human monocytic cell line-based potency assay |
WO2013139728A1 (en) | 2012-03-19 | 2013-09-26 | Synthon Bv | Glatiramer acetate human monocyte cell-based potency assay |
US20140045740A1 (en) * | 2012-08-13 | 2014-02-13 | Momenta Pharmaceuticals, Inc. | Analysis of glatiramer acetate |
CA2884267A1 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
WO2014060942A2 (en) * | 2012-10-20 | 2014-04-24 | Mahesh Kandula | Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases |
WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
SI2774639T1 (sl) | 2013-03-08 | 2015-05-29 | Teva Pharmaceutical Industries, Ltd. | Injektorska naprava za brizgo, primerna za večkratno uporabo |
EP2774640B1 (en) | 2013-03-08 | 2014-12-31 | Teva Pharmaceutical Industries, Ltd. | Re-useable injector device for syringe |
AU2014244550B2 (en) | 2013-03-14 | 2018-11-01 | Mylan Inc. | Glatiramer acetate response biomarker mRNA potency assay |
WO2014173463A1 (en) | 2013-04-26 | 2014-10-30 | Synthon Bv | Glatiramer acetate human monocytic cell line-based potency assay |
WO2014182966A1 (en) | 2013-05-10 | 2014-11-13 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
CN103265624B (zh) * | 2013-05-27 | 2015-04-22 | 成都圣诺生物制药有限公司 | 格拉替雷的制备方法 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
CA2928084A1 (en) | 2013-10-24 | 2015-04-30 | Mylan Inc. | Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
JP2017503169A (ja) | 2013-12-31 | 2017-01-26 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断 |
RU2690670C2 (ru) | 2014-03-12 | 2019-06-05 | Ида Рисерч Энд Дивелопмент Ко., Лтд | Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US11047855B2 (en) | 2015-03-01 | 2021-06-29 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
CN113637040A (zh) | 2015-08-19 | 2021-11-12 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
ES2744179T3 (es) | 2015-09-24 | 2020-02-24 | Chemi Spa | Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas |
ES2707500T3 (es) | 2015-11-23 | 2019-04-03 | Chemi Spa | Análisis mediante RP-HPLC de mezclas de polipéptidos complejos |
CN107522774B (zh) * | 2016-06-22 | 2021-07-02 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法 |
WO2018002930A1 (en) | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
BR112019003131A2 (pt) | 2016-08-28 | 2019-05-21 | Mapi Pharma Ltd. | processo para preparar micropartículas contendo acetato de glatirâmero |
FI3506921T3 (fi) | 2016-08-31 | 2023-07-21 | Mapi Pharma Ltd | Glatirameeriasetaattia käsittäviä depot-järjestelmiä |
CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
WO2018211486A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells |
CA3062123A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
WO2019175869A1 (en) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Treatment of a heart disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849550A (en) * | 1971-04-21 | 1974-11-19 | Yeda Res & Dev | Therapeutic copolymer |
CN1042162A (zh) * | 1988-08-22 | 1990-05-16 | 生物聚合体有限公司 | 合成含有氨基酸和/或肽的接枝共聚物 |
CN1054009A (zh) * | 1990-02-13 | 1991-08-28 | 武田药品工业株式会社 | 缓释微胶囊 |
CN1073980A (zh) * | 1991-11-12 | 1993-07-07 | 纳幕尔杜邦公司 | 胶原样多肽 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444760A (en) | 1983-06-17 | 1984-04-24 | Merck & Co., Inc. | Purification and characterization of a protein fibroblast growth factor |
JPS6053535A (ja) | 1983-09-02 | 1985-03-27 | Nitto Boseki Co Ltd | 規則性ポリアミノ酸樹脂の製造方法 |
SU1182051A1 (ru) | 1984-04-28 | 1985-09-30 | Таджикский государственный университет им.В.И.Ленина | Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина |
DE3681144D1 (de) | 1985-06-18 | 1991-10-02 | Univ Emory | Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren. |
DD257174A3 (de) | 1985-12-20 | 1988-06-08 | Ve Forschungszentrum Biotechno | Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease |
SU1469826A1 (ru) | 1986-05-30 | 1995-11-20 | Институт Высокомолекулярных Соединений Ан Ссср | Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения |
US4828706A (en) | 1988-03-07 | 1989-05-09 | Spectrum Medical Industries | Process for performing a dialysis operation |
DE8900366U1 (zh) * | 1989-01-13 | 1989-08-03 | Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De | |
CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
SU1690368A1 (ru) | 1989-07-20 | 1995-08-20 | Институт Высокомолекулярных Соединений Ан Ссср | Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения |
DE3930733A1 (de) | 1989-09-14 | 1991-03-28 | Roehm Gmbh | Verfahren zur herstellung eines komplexierten arzneimittels |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
AU7368798A (en) | 1997-05-06 | 1998-11-27 | Quanta Vision | Tissue analysis apparatus |
JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー1、関連ペプチド及びポリペプチドならびにそれらによって処理されたt細胞の使用 |
US6936539B2 (en) * | 2003-09-24 | 2005-08-30 | Micron Technology, Inc. | Antireflective coating for use during the manufacture of a semiconductor device |
-
1995
- 1995-05-22 IL IL11381295A patent/IL113812A/xx not_active IP Right Cessation
- 1995-05-22 US US08/447,146 patent/US5800808A/en not_active Expired - Lifetime
- 1995-05-23 CN CNB951941011A patent/CN1174753C/zh not_active Expired - Lifetime
- 1995-05-23 HU HU9603243A patent/HU223473B1/hu active Protection Beyond IP Right Term
- 1995-05-23 MD MD97-0024A patent/MD1443G2/ro unknown
- 1995-05-23 GE GEAP19953466A patent/GEP20002205B/en unknown
- 1995-05-23 NZ NZ287335A patent/NZ287335A/xx not_active IP Right Cessation
- 1995-05-23 PL PL95317331A patent/PL181026B1/pl unknown
- 1995-05-23 CN CNB200410064296XA patent/CN1310673C/zh not_active Expired - Lifetime
- 1995-05-23 BR BRPI9507758-8A patent/BRPI9507758B1/pt unknown
- 1995-05-23 UA UA96114382A patent/UA62908C2/uk unknown
- 1995-05-23 DE DE69525340T patent/DE69525340T2/de not_active Expired - Lifetime
- 1995-05-23 AU AU26021/95A patent/AU2602195A/en not_active Abandoned
- 1995-05-23 SI SI9530577T patent/SI0762888T1/xx unknown
- 1995-05-23 BR BR9507758A patent/BR9507758A/pt active IP Right Grant
- 1995-05-23 EE EE9600170A patent/EE03423B1/xx unknown
- 1995-05-23 AT AT95920632T patent/ATE212857T1/de active
- 1995-05-23 ES ES95920632T patent/ES2172586T3/es not_active Expired - Lifetime
- 1995-05-23 KR KR1019960706612A patent/KR100403750B1/ko not_active IP Right Cessation
- 1995-05-23 SK SK1493-96A patent/SK283699B6/sk not_active IP Right Cessation
- 1995-05-23 WO PCT/US1995/006551 patent/WO1995031990A1/en active IP Right Grant
- 1995-05-23 TJ TJ96000421A patent/TJ392B/xx unknown
- 1995-05-23 DK DK95920632T patent/DK0762888T3/da active
- 1995-05-23 CA CA002191088A patent/CA2191088C/en not_active Expired - Lifetime
- 1995-05-23 DE DE2002199030 patent/DE10299030I1/de active Pending
- 1995-05-23 CZ CZ19963410A patent/CZ292247B6/cs not_active IP Right Cessation
- 1995-05-23 JP JP7530519A patent/JPH10500955A/ja active Pending
- 1995-05-23 PT PT95920632T patent/PT762888E/pt unknown
- 1995-05-23 EP EP95920632A patent/EP0762888B1/en not_active Expired - Lifetime
-
1996
- 1996-11-15 FI FI964600A patent/FI120236B/fi not_active IP Right Cessation
- 1996-11-22 NO NO19964976A patent/NO324528B1/no not_active IP Right Cessation
-
1998
- 1998-02-27 US US09/032,647 patent/US6054430A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,334 patent/US6048898A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,616 patent/US5981589A/en not_active Expired - Lifetime
- 1998-07-02 HK HK98108818A patent/HK1008657A1/xx not_active IP Right Cessation
-
2000
- 2000-01-05 IL IL13389000A patent/IL133890A0/xx not_active IP Right Cessation
- 2000-02-22 US US09/510,466 patent/US6362161B1/en not_active Expired - Lifetime
- 2000-02-22 US US09/510,141 patent/US6342476B1/en not_active Expired - Lifetime
-
2001
- 2001-12-14 US US10/014,477 patent/US6620847B2/en not_active Expired - Lifetime
-
2002
- 2002-07-29 NL NL300096C patent/NL300096I2/nl unknown
- 2002-08-05 LU LU90987C patent/LU90987I2/fr unknown
- 2002-08-09 JP JP2002233094A patent/JP3715600B2/ja not_active Expired - Lifetime
-
2003
- 2003-07-10 US US10/615,865 patent/US6939539B2/en not_active Expired - Lifetime
-
2005
- 2005-04-05 US US11/098,432 patent/US7199098B2/en not_active Expired - Fee Related
-
2007
- 2007-01-23 US US11/656,505 patent/US7625861B2/en not_active Expired - Fee Related
-
2011
- 2011-09-26 US US13/244,737 patent/US8367605B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849550A (en) * | 1971-04-21 | 1974-11-19 | Yeda Res & Dev | Therapeutic copolymer |
CN1042162A (zh) * | 1988-08-22 | 1990-05-16 | 生物聚合体有限公司 | 合成含有氨基酸和/或肽的接枝共聚物 |
CN1054009A (zh) * | 1990-02-13 | 1991-08-28 | 武田药品工业株式会社 | 缓释微胶囊 |
CN1073980A (zh) * | 1991-11-12 | 1993-07-07 | 纳幕尔杜邦公司 | 胶原样多肽 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104371012A (zh) * | 2013-08-12 | 2015-02-25 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
US10259909B2 (en) | 2014-09-26 | 2019-04-16 | Hybio Pharmaceutical Co., Ltd. | Method for preparing glatiramer acetate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1310673C (zh) | 含多肽的多分散混合物的组合物及其药物组合物 | |
CN103533951B (zh) | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 | |
MXPA97003362A (en) | Conjugates of bdnf and nt-3 with a polymer solubleen a | |
RU2161489C2 (ru) | Усовершенствованный сополимер-1 в сополимерных композициях | |
AU2004202245B2 (en) | Copolymer-1 Improvements in Compositions of Copolymers | |
AU741590B2 (en) | Copolymer-1 improvements in compositions of copolymers | |
JP3002213B2 (ja) | ペプチドおよびこのペプチドを含有する薬剤 | |
AU775214B2 (en) | Copolymer-1 improvements in compositions of copolymers | |
RU2402576C1 (ru) | Пептидный сополимер, способ его получения и фармацевтическая композиция на его основе |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150523 Granted publication date: 20070418 |